𝛼SK or Searchbullish
Imugene Ltd - Two for two in BTKi azer-cel cohort
SUMMARY
- Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging pipeline into a highly-focused vehicle concentrating on CAR-T.
- It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers.
- IMU has announced that its second patient in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort (Cohort 3) of the azer-cel Phase 1b study has achieved a complete response (CR – where the patient has no detectable evidence of cancer after treatment).
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Imugene Ltd - Two for two in BTKi azer-cel cohort02 Jul 2026
x